KRT17

Across TCGA pan-cancer cohorts, KRT17 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of KRT17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where KRT17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KRT17 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where KRT17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+2.285	<.001	11	view →
COAD	Female	III,IV	+0.976	<.001	11	view →
LSCC	All	III,IV	+1.865	<.001	8	view →
PDAC	Male	All	+1.643	<.001	8	view →
CCRCC	Male	III,IV	−0.837	<.001	6	view →
LUAD	All	All	+0.464	.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

KRT17–HNSC

Open the HNSC breakdown →